Results 21 to 30 of about 10,368,058 (146)

Current Treatments to Control African Trypanosomiasis and One Health Perspective

open access: yesMicroorganisms, 2022
Human African Trypanosomiasis (HAT, sleeping sickness) and Animal African Trypanosomiasis (AAT) are neglected tropical diseases generally caused by the same etiological agent, Trypanosoma brucei.
Alberto Venturelli   +9 more
doaj   +1 more source

Accuracy of five algorithms to diagnose gambiense human African trypanosomiasis. [PDF]

open access: yes, 2011
Algorithms to diagnose gambiense human African trypanosomiasis (HAT, sleeping sickness) are often complex due to the unsatisfactory sensitivity and/or specificity of available tests, and typically include a screening (serological), confirmation ...
Francesco Checchi   +19 more
core   +2 more sources

Identification of sVSG117 as an immunodiagnostic antigen and evaluation of a dual-antigen lateral flow test for the diagnosis of human african trypanosomiasis [PDF]

open access: yes, 2014
The diagnosis of human African trypanosomiasis (HAT) caused by Trypanosoma brucei gambiense relies mainly on the Card Agglutination Test for Trypanosomiasis (CATT). There is no immunodiagnostic for HAT caused by T. b. rhodesiense.
Sastry Lalitha   +20 more
core   +2 more sources

Kynurenine pathway inhibition reduces central nervous system inflammation in a model of human African trypanosomiasis [PDF]

open access: yes, 2009
Human African trypanosomiasis, or sleeping sickness, is caused by the protozoan parasites <i>Trypanosoma brucei rhodesiense</i> or <i>Trypanosoma brucei gambiense</i>, and is a major cause of systemic and neurological disability ...
Barrett, M.P.   +4 more
core   +1 more source

Hypocretin and Human African Trypanosomiasis [PDF]

open access: yesSleep, 2008
To detail clinical and polysomnographic characteristics in patients affected with Trypanosoma brucei gambiense (Tb.g.) human African trypanosomiasis (HAT) at different stages of evolution and to measure and compare cerebrospinal fluid (CSF) levels of hypocretin-1 with narcoleptic patients and neurologic controls.Twenty-five untreated patients affected ...
Yves, Dauvilliers   +6 more
openaire   +2 more sources

A molecular mechanism for eflornithine resistance in African trypanosomes [PDF]

open access: yes, 2010
Human African trypanosomiasis, endemic to sub-Saharan Africa, is invariably fatal if untreated. Its causative agent is the protozoan parasite Trypanosoma brucei.
Creek, Darren   +7 more
core   +4 more sources

Human African trypanosomiasis caused by Trypanosoma brucei gambiense: The first case report in China

open access: yesInternational Journal of Infectious Diseases, 2019
We report the first imported case in China of human African trypanosomiasis (HAT), caused by Trypanosoma brucei gambiense, in a sailor returning from Gabon in 2014.
Nian Chen   +4 more
doaj   +1 more source

Human African trypanosomiasis

open access: yesBMJ, 2002
The re-emergence of sleeping sickness presents a major public health problem Human African trypanosomiasis or sleeping sickness is one of the most important but equally most neglected tropical infections. It is caused by a protozoan, Trypanosoma brucei ,which is transmitted to humans through the bite of a tsetse fly ( Glossina spp).1 Patchy ...
August, Stich   +2 more
openaire   +3 more sources

African trypanosomiasis in travelers returning to the United Kingdom. [PDF]

open access: yes, 2002
Two returning safari tourists with African trypanosomiasis were admitted to the Hospital for Tropical Diseases, London, in a 3-day period, compared with six cases in the previous 14 years.
Bailey, J Wendi   +17 more
core   +1 more source

Computer-aided identification of Trypanosoma brucei uridine diphosphate galactose 4'-epimerase inhibitors : toward the development of novel therapies for African sleeping sickness [PDF]

open access: yes, 2010
Trypanosoma brucei, the causative agent of human African trypanosomiasis, affects tens of thousands of sub-Saharan Africans. As current therapeutics are inadequate due to toxic side effects, drug resistance, and limited effectiveness, novel therapies are
Durrant, Jacob D.   +3 more
core   +5 more sources

Home - About - Disclaimer - Privacy